Cardiotoxicity
| Cardiotoxicity | |
|---|---|
| Synonyms | |
| Pronounce | |
| Specialty | Cardiology, Oncology |
| Symptoms | |
| Complications | |
| Onset | |
| Duration | |
| Types | |
| Causes | Exposure to cardiotoxic agents |
| Risks | |
| Diagnosis | Echocardiogram, Electrocardiogram, Blood tests |
| Differential diagnosis | |
| Prevention | |
| Treatment | |
| Medication | |
| Prognosis | |
| Frequency | |
| Deaths | |
Cardiotoxicity refers to damage to the heart by harmful chemicals. As a significant side effect of certain medications, particularly chemotherapy agents and other drugs, it poses a serious risk for patients undergoing treatment for various conditions, including cancer. The understanding and management of cardiotoxicity are crucial in the fields of cardiology and oncology.
Causes[edit]
Cardiotoxicity can be caused by numerous agents including:
- Chemotherapy drugs, such as anthracyclines (e.g., doxorubicin), and monoclonal antibodies (e.g., trastuzumab)
- Radiation therapy, especially when the heart is within the radiation field
- Some targeted therapies and other medications, such as tyrosine kinase inhibitors
- Excessive exposure to certain environmental toxins
Mechanisms[edit]
The mechanisms of cardiotoxicity vary depending on the causative agent. For example, anthracyclines induce cardiotoxicity primarily through the generation of free radicals, which damage the cardiac muscle. Trastuzumab, on the other hand, can lead to heart dysfunction by interfering with HER2 signals, which are important for heart cell survival and repair.
Symptoms[edit]
Symptoms of cardiotoxicity may include:
Diagnosis[edit]
Diagnosis of cardiotoxicity generally involves:
- Echocardiogram to assess heart function
- Electrocardiogram (ECG) to monitor heart rhythm
- Blood tests to measure cardiac biomarkers
Prevention and Management[edit]
Prevention and management strategies for cardiotoxicity include:
- Regular monitoring of heart function during and after treatment
- Use of cardioprotective agents
- Dose modification or discontinuation of the cardiotoxic drug
Prognosis[edit]
The prognosis for patients with cardiotoxicity varies based on the severity of the damage and the response to management strategies. Early detection and intervention are critical for improving outcomes.
See also[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
